The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Nelkarmi (neladalkib), a novel ALK-selective tyrosine kinase inhibitor, for adults with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have previously received specific therapies. The approval, announced November 17, 2026, comes ahead of the agency’s official target date, and is based on promising efficacy data from the Phase I/II ALKOVE-1 trial.
Nelkarmi, now part of GSK’s oncology portfolio following its acquisition of Nuvalent, Inc. earlier in 2026, is indicated for adults with locally advanced or metastatic ALK-positive NSCLC who have previously received either one prior ALK tyrosine kinase inhibitor (TKI) — specifically alectinib — or two or more prior ALK TKIs in combination with platinum-based chemotherapy.
Meaningful Tumor Responses in Difficult-to-Treat Patients
The ALKOVE-1 study enrolled 222 adults with previously treated ALK-positive NSCLC. Among patients who had received only alectinib previously, the confirmed overall response rate (ORR) was 49%, with more than half maintaining a response for at least a year. In those who had received two or more prior ALK TKIs and chemotherapy, the ORR reached 32%, with over half of these responders also sustaining responses for a year or more. Notably, the drug showed intracranial efficacy in patients with baseline central nervous system metastases — a particularly challenging complication in this cancer type.
“This approval provides a new option for patients whose disease has progressed despite prior targeted therapies,” the FDA stated in its announcement. The agency emphasized that approval was granted based on tumor response rate and duration of response; continued approval remains contingent on confirmatory trials currently underway.
Safety Profile and Ongoing Requirements
The most common side effects reported in clinical studies included hepatotoxicity, musculoskeletal pain, constipation, dysgeusia (taste disturbances), peripheral neuropathy, edema, and fatigue. Serious adverse reactions such as hepatotoxicity and pneumonia led to permanent discontinuation in 5% of treated patients, underscoring the need for careful monitoring.
Nelkarmi’s regulatory journey was marked by expedited review designations from the FDA, including Breakthrough Therapy, Orphan Drug, and Priority Review status. The accelerated approval highlights both the significant unmet need for effective treatments in heavily pretreated ALK-positive NSCLC and the urgency for ongoing data from confirmatory trials.
This is GSK’s second newly approved lung cancer drug in 2026, following the earlier green light for Jideytro (zidesamtinib). No details about pricing or wide commercial availability for Nelkarmi were disclosed as of the approval date. The ongoing ALKAZAR phase III study will further evaluate its use in patients not previously treated with ALK TKIs.
For patients and clinicians, the approval represents new hope amid a challenging clinical landscape, with further evidence still needed to solidify Nelkarmi’s place in future standards of lung cancer care.